Alan Taylor
Home Health · Eddystone, PANPI 1104898352
Payments from drug & device makers
Across 182 payments — averaging $26.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Mannkind Corporation$1K
- Lilly USA, LLC$574
- Bioventus LLC$492
- Medtronic$421
- Collegium Pharmaceutical, Inc.$403
- Novo Nordisk$335
- plus $1K from 20 others
What the payments were for
- Travel & lodging$3818%
- Food & beverage$4,30690%
- Education$431%
- Gifts$591%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Mannkind Corporation | 63 | $1,305 |
| Lilly USA, LLC | 25 | $574 |
| Bioventus LLC | 2 | $492 |
| Medtronic | 12 | $421 |
| Collegium Pharmaceutical, Inc. | 19 | $403 |
| Novo Nordisk | 12 | $335 |
| Xeris Pharmaceuticals, Inc. | 8 | $177 |
| Boston Scientific | 1 | $142 |
| Sanofi-aventis U.S. LLC | 4 | $104 |
| AstraZeneca | 6 | $104 |
| Sequel Med Tech, LLC | 4 | $103 |
| Tolmar, Inc. | 4 | $97 |
| Amgen | 1 | $59 |
| Merck | 3 | $57 |
| Tandem Diabetes Care, Inc. | 2 | $55 |
| Intuity Medical Inc | 3 | $55 |
| Ascensia Diabetes Care US Inc. | 2 | $54 |
| Acella Pharmaceuticals, LLC | 2 | $46 |
| Insulet Corporation | 2 | $40 |
| Averitas Pharma Inc. | 1 | $35 |
| AbbVie | 1 | $26 |
| Radius Health, Inc. | 1 | $26 |
| Abbott | 1 | $22 |
| GRT US Holding, Inc. | 1 | $22 |
| BETA Bionics, Inc. | 1 | $21 |
| Dexcom, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
Too few home health providers in Pennsylvaniato place this figure against a meaningful peer group, so we don't.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OxycontinOxycodone Hcl | 176 | $292,822 |
| Nucynta ErTapentadol Hcl | 43 | $84,701 |
| Xtampza ErOxycodone Myristate | 73 | $77,306 |
| Oxycodone Hcl | 1,145 | $46,329 |
| Fentanyl | 161 | $25,609 |
| MounjaroTirzepatide | 20 | $22,324 |
| ArexvyRsvpref3 Antigen/As01e/Pf | 70 | $20,281 |
| Morphine Sulfate ErMorphine Sulfate | 314 | $16,085 |
| Hydromorphone ErHydromorphone Hcl | 12 | $10,436 |
| ShingrixVaricella-Zoster Ge/As01b/Pf | 47 | $10,045 |
| Buprenorphine | 30 | $8,405 |
| Hydromorphone Hcl | 144 | $7,844 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 133 | $5,651 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 123 | $4,667 |
| Gabapentin | 192 | $4,030 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Collegium Pharmaceutical, Inc.Nucynta Er, Xtampza Er | $403 | $162,007116 claims |
| Lilly USA, LLCMounjaro | $574 | $22,32420 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few home health providers in Pennsylvaniaon file to place this against a meaningful peer group, so we don't.
Other home health in Eddystone
- Candace PerryPhiladelphia$30
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.